Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer
Abstract Pancreatic cancer is a lethal disease with poor prognosis.Gemcitabine has been the first line systemic treatment for pancreatic cancer.However, the rapid development of drug resistance has been a major hurdle in gemcitabine therapy leading to unsatisfactory patient outcomes.With the recent renewed understanding of glutamine metabolism invo